

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A fusion protein comprising

- i) A a first polypeptide sequence derived from a lectin-complement pathway activating protein or a functional homologue thereof at least 70% identical to said lectin-complement pathway activating protein, wherein said first polypeptide sequence is capable of activating protein, wherein said first polypeptide sequence is capable of activating the lectin-complement pathway; and
- ii) A a second polypeptide sequence derived from a collectin or a functional homologue thereof at least 70% identical to said collectin, wherein said second polypeptide sequence is capable of associating with one or more carbohydrates;

wherein said complement activating protein is not a collectin.

2. (Cancelled)

3. (Original) The fusion protein according to claim 1, wherein said first polypeptide sequence is capable of associating with at least one MASP protein.
4. (Original) The fusion protein according to claim 1, wherein said first polypeptide sequence is capable of associating with a MASP protein selected from the group consisting of MASP-1, MASP-2 and MASP-3 or functional homologues or variants hereof.
5. (Original) The fusion protein according to claim 1, wherein the complement activating protein is a ficolin.
6. (Original) The fusion protein according to claim 5, wherein the ficolin is selected from the group consisting of L-ficolin, H-ficolin and M-ficolin.
7. (Original) The fusion protein according to claim 5, wherein the ficolin is L-ficolin.
8. (Cancelled)
9. (Original) The fusion protein according to claim 1, wherein the first polypeptide sequence comprises the collagen-like

domain of a ficolin or a functional homologue or variant thereof.

10. (Cancelled)

11. (Original) The fusion protein according to claim 1, wherein the first polypeptide sequence comprises the cysteine-rich region of a ficolin or a functional homologue thereof.

12. (Cancelled)

13. (Original) The fusion protein according to claim 1, wherein the first polypeptide sequence comprises the cysteine-rich region and the collagen-like domain of a ficolin or a functional homologue or variant thereof.

14. (Cancelled)

15. (Currently Amended) The fusion protein according to claim 1, wherein the first polypeptide sequence comprises amino acids 1-77 of the L-ficolin sequence of figure 1 (SEQ ID. NO 125) ~~SEQ ID. NO 1.~~

16. (Cancelled)

17. (Original) The fusion protein according to claim 1, wherein the collectin is selected from the group consisting of MBL (mannose-binding lectin), SP-A (lung surfactant protein A), SP-D (lung surfactant protein D), BK (or BC, bovine conglutinin) and CL-43 (collectin-43).

18. (Original) The fusion protein according to claim 17, wherein the collectin is MBL.

19. (Cancelled)

20. (Original) The fusion protein according to claim 1, wherein the second polypeptide sequence comprises the CRD domain of a collectin or a functional homologue or variant thereof.

21. (Original) The fusion protein according to claim 1, wherein the second polypeptide sequence comprises the CRD domain of MBL.

22. (Original) The fusion protein according to claim 1, wherein the second polypeptide sequence comprises the neck region of MBL.
23. (Original) The fusion protein according to claim 1, wherein the second polypeptide sequence comprises the collagen-like domain of MBL.
24. (Original) The fusion protein according to claim 1, wherein the second polypeptide sequence comprises the neck region and the CRD domain of MBL.
25. (Original) The fusion protein according to claim 1, wherein the second polypeptide sequence comprises the collagen-like domain, the neck region and the CRD domain of MBL.
26. (Currently Amended) The fusion protein according to claim 1, wherein the second polypeptide sequence comprises amino acids 80-228 of the MBL sequence shown in figure 2 (SEQ ID. No 126)~~SEQ ID. NO 2.~~
27. (Original) The fusion protein according to claim 1, wherein the fusion protein comprises the the cysteine-rich

region and the collagen-like domain of L-ficolin and the CRD domain of MBL.

28. (Original) The fusion protein according to claim 1, wherein the fusion protein comprises the cysteine-rich region of L-ficolin and the collagen-like domain, the neck region and the CRD domain of MBL.
29. (Currently Amended) The fusion protein according to claim 1, wherein the fusion protein comprises the amino acid sequence as defined by the sequence shown in figure 3 (SEQ ID. NO. 127)~~SEQ ID. NO. 3~~, or a functional homologue thereof at least 70% identical thereto.
30. (Currently Amended) The fusion protein according to claim 1, wherein the fusion protein consists of the amino acid sequence as defined by the sequence shown in figure 3 (SEQ ID. NO 127)~~SEQ ID. NO. 3~~.
31. (Currently Amended) An isolated nucleic acid comprising a nucleotide sequence encoding the fusion protein according to ~~any of claims 1 to 30~~ claim 1.

32. (Original) A vector comprising the nucleic acid sequence according to claim 31.

33. (Original) A cell comprising the vector according to claim 32.

34. - 36. (Cancelled)

37. (Currently Amended) A method of prevention and/or treatment of ~~a clinical condition~~ an infection in an individual in need thereof comprising administering to said individual an effective amount of the fusion protein according to ~~any of claims 1 to 30~~ claim 1.

38. (Cancelled)

39. (Original) The method according to claim 37, wherein the individual is a human being.

40. (Original) The method according to claim 37, wherein the individual is a human being suffering from an increased risk of acquiring an infection.

41. (Original) The method according to claim 37, wherein the individual is a human being with subnormal serum MBL level.

42. (Original) The method according to claim 37, wherein the individual is a human being with normal serum MBL level.

43. - 48. (Cancelled)

49. (Currently Amended) A ~~medicament~~ pharmaceutically acceptable composition for the treatment or prevention of a clinical condition in an individual in need thereof, comprising the fusion protein according to ~~any of claims 1 to 30~~ claim 1, and a pharmaceutically acceptable carrier.

50. - 51. (Cancelled)